Safety and Immunogenicity Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged Years 3-60

NCT02806804 | Unknown Phase 3

• 1 other identifier: cycdc2016-1
• Study Type: interventional
• Target: 2,400
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study evaluates the safety and immunogenicity of the quadrivalent influenza virus vaccine in healthy people aged years 3-60.Subjects will be randomly divided into 3 groups,receiving the test vaccine, commercially available trivalent influenza vaccine and trivalent influenza vaccine containing new influenza B component respectively. Each group has 800 subjects,2400 in total.

Conditions

Quadrivalent Influenza Virus Vaccine

Keywords

vaccine; safety; immunogenicity

Outcome Measures

Primary Outcomes (2)

• Evaluate serum antibody titers of quadrivalent influenza Vaccine in healthy people.

  The serum antibody titers will be evaluated at 28 days after vaccination.

  28 days

• Evaluate the Rate of Adverse reactions of quadrivalent influenza Vaccine in healthy people.

  Adverse reactions associated with vaccine will be observed in subjects after vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy.

  28 days

Study Arms (3)

one dose test vaccine

EXPERIMENTAL

One dose of quadrivalent influenza virus vaccine will be randomly given in aged 3-60 years old.

Biological: one dose test vaccine

one dose commercially available trivalent influenza vaccine

EXPERIMENTAL

One dose of trivalent influenza virus vaccine will be randomly given in aged 3-60 years old.

Biological: one dose commercially available trivalent influenza vaccine

One dose quadrivalent influenza virus vaccine

EXPERIMENTAL

One dose of quadrivalent influenza virus vaccine (trivalent influenza virus vaccine added to a new influenza B component) will be randomly given in aged 3-60 years old.

Biological: One dose of Quadrivalent Influenza Virus Vaccine

Interventions

one dose test vaccine BIOLOGICAL

one dose test vaccine

one dose commercially available trivalent influenza vaccine BIOLOGICAL

one dose commercially available trivalent influenza vaccine

One dose of Quadrivalent Influenza Virus Vaccine BIOLOGICAL

One dose quadrivalent influenza virus vaccine

Eligibility Criteria

• Age: 3 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• healthy subjects more than 3 years old, and the subjects can be informed consent, and sign the informed consent.
• the subjects and his guardians can obey the demands of the scheme .
• Axillary temperature less than 37℃

You may not qualify if:

• The people who has flu or influenza-like symptoms(fever \<axillary temperature ≥38 ℃\>, cough or sore throat) within 3 months
• The people who has vaccinated influenza vaccine in 3years.
• The people who has a vaccine allergies, or who allergic to any kind of composition in experimental vaccine, such as eggs, ovalbumin etc.
• The people who has serious side effects to vaccine, such as allergy, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain.
• the subject who has symptoms of acute infection within a week.
• Autoimmune diseases or Immune function defect, people has immunosuppressive therapy, cytotoxic treatment or inhaled corticosteroids in the past 6 months.
• People has congenital malformations, developmental disorder or serious chronic diseases( such as Down's syndrome, diabetes, Sickle cell anemia or nerve system disease)
• People has asthma Unstable that need emergency treatment, hospitalization, intubation, oral or intravenous corticosteroid in the past 2 years.
• Diagnosed abnormal coagulation(Lack of clotting factors,Clotting disorders,Platelet abnormality) or significant bruising or coagulopathy
• people has history or family history of convulsions, seizures, encephalopathy and psychiatric.
• alienia, functional asplenia, and alienia or splenectomy in any situation.
• Serious neurological disorders such as Green Barry syndrome.
• people who has received blood products or immunoglobulin products in the past one months.
• people who has received other study drug in the past one month.
• people who received live attenuated vaccine, subunit vaccine or inactivated vaccine.

Sponsors & Collaborators

• Beijing Chaoyang District Centre for Disease Control and Prevention: lead

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 15, 2016
• First Posted: June 21, 2016
• Study Start: May 1, 2016
• Primary Completion: June 1, 2016
• Last Updated: June 21, 2016

Record last verified: 2016-06